Physician profile
Bruce W Lee
NPI 1952391740
$2,533.19
in general payments reported to CMS, 2019-2025
26 companies · $966 in 2025
The $966 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.86 · 2020: $28.13 · 2021: $228 · 2022: $536 · 2023: $382 · 2024: $357 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $360.87 | 2021-2025 | |
| Novo Nordisk INC | $325.60 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $309.75 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $264.60 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.37 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $198.96 | 2022-2025 | Trelegy Ellipta, Penmenvy, Bexsero |
| Pfizer INC. | $112.53 | 2024-2025 | |
| Shield Therapeutics INC | $110.97 | 2025 | |
| Janssen Pharmaceuticals, INC | $93.03 | 2021-2022 | |
| Genzyme Corporation | $84.27 | 2022-2023 | |
| Lilly USA, LLC | $67.89 | 2021-2022 | |
| Sanofi Pasteur INC. | $57.64 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $56.33 | 2023-2024 | |
| Seqirus USA INC | $37.56 | 2025 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $34.77 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $34.74 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $31.58 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.91 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $16.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.53 | 2021 | |
| Abbott Laboratories | $15.03 | 2023 | Freestyle Libre 2 |
| Dexcom, INC. | $14.79 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $14.70 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $14.59 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $14.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.77 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.